The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Commentary|Articles|March 31, 2025
The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective
Author(s)Courtney Flaherty
Fact checked by: Caroline Seymour
Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.
Advertisement
Advertisement
Five years after the onset of the COVID-19 pandemic, the oncology field continues to grapple with its repercussions. From fundamental shifts in patient management, including the introduction of telemedicine, to trial disruptions and workforce challenges, the pandemic has reshaped every aspect of oncology care. Although some of these adaptations offer unique benefits, others require strategic solutions, and the oncology community must continue to adapt and innovate to ensure optimal patient outcomes.
Related to this article
R. Lor Randall, MD, FACS, discusses AI in musculoskeletal tumor diagnosis, surgical planning and robotics, and validation of AI tools.
MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.
An FDA advisory committee voted in favor of the benefits of the Galleri MCED test outweighing its risks in patients 50 years of age and older.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Advertisement
Advertisement